ImmunityBio, Inc. (NASDAQ: IBRX) reported Q2 EPS of ($0.10), $0.01 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $26.43 million versus the consensus estimate of $21.49 million.

For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.